Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,766.50
Bid: 1,766.00
Ask: 1,766.50
Change: 36.50 (2.11%)
Spread: 0.50 (0.028%)
Open: 1,735.50
High: 1,766.50
Low: 1,735.00
Prev. Close: 1,730.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-European shares suffer as trade jitters, weak data weigh

Thu, 22nd Mar 2018 17:40

* STOXX 600 down 1.6 pct to 2-week low

* Banks, miners, tech lead sectoral fallers

* Reckitt gains after pulling out of Pfizer race(Adds details, closing prices)

By Helen Reid and Danilo Masoni

LONDON, March 22 (Reuters) - Concerns about trade sentEuropean shares tumbling on Thursday as the United Statesprepared to announce hefty tariffs on Chinese imports, withbanks, basic resources stocks and tech the worst-performing.

U.S. President Donald Trump signed a presidential memorandumthat could impose tariffs on up to $60 billion in Chineseimports.

Separately, the European Union secured an exemption fromU.S. tariffs on steel and aluminium imports set to come intoforce on Friday.

The pan-European STOXX 600 index fell 1.6 percentto its lowest level in more than two weeks, while Germany'sexporter- and industrials-heavy DAX fell 1.7 percent.

The mood was also dampened by a weaker than forecastbusiness activity survey. Euro zone businesses rounded off thefirst quarter of 2018 with their slowest growth in over a year,much weaker than expected, as new business took another hit froma stubbornly strong euro.

"Business sentiment has to be monitored carefully in thecoming months, especially if trade tensions intensify, becauseany further significant deterioration in confidence indicatorsmight signal that the balance of risks starts shifting to thedownside," said UniCredit head of macro research Marco Valli.

Banks, which have been penalized recently weaker thanexpected macro economic data in Europe, were among the leadinglosers on Thursday. Their sectoral index fell 2.5percent to an 11-month low. The sector also suffered after theU.S. Federal Reserve surprised the market with less hawkish rateguidance.

Deutsche Bank declined 2.9 percent, still weakafter sharp losses in the previous session when the bank'sfinance chief said a strong euro and higher funding costs wouldhave a 450 million euro impact on revenues.

Commerzbank tumbled 6.2 percent after a downgradefrom Kepler Cheuvreux.

Basic resources stocks led sectoral losers, down 2.9percent after copper reversed earlier gains to fall tothree-month lows as escalating concern about U.S. plans to levyduties on Chinese imports.

Tech stocks < .SX8P> 2.1 as tariffs on China were expectedto target the high-tech sector.

Chipmakers ams, STMicro, and Infineon, which have led the recent tech stock rally and arefirmly embedded in international supply chains, all fell. .

Deal developments and earnings continued to drive Europeanstock moves.

Reckitt Benckiser shares shone, jumping 4.8 percentafter the British consumer products firm pulled out of thebidding for Pfizer's consumer health unit.

The move reflected relief in the market that Reckitt wouldavoid over-levering or issuing shares for the acquisition.

GlaxoSmithKline, now seen as having a better chanceof buying the Pfizer business, declined 1.7 percent.

Disappointing 2017 results sent United Internetshares down 9.5 percent. Subsidiary Drillisch fell 5.7percent.

Also in tech, Ingenico suffered a 3.4 percent lossafter Kepler Cheuvreux downgraded it, saying full-year guidancenow looked "challenging".

Tech and engineering consultancy Altran fell 3.3percent after launching a share capital increase of 750 millioneuros.

The world’s no.2 cement maker Heidelberg Cementfell 2.3 percent after it announced a dividend slightly short ofanalysts’ average expectations.

Bayer fell 1.4 percent after Australian and EUregulators approved the firm's takeover of Monsanto. "Halfwaythere," wrote UBS analysts, adding all eyes were now on the U.S.Department of Justice, yet to approve the deal.

Overall, with results season drawing to a close, analystswere becoming more negative on the earnings outlook for Europeanstocks.

(Reporting by Helen Reid and Danilo Masoni, Editing by RichardBalmforth and Hugh Lawson)

More News
25 Sep 2023 08:37

TOP NEWS: GSK's Arexvy vaccine approved for adults over 60 in Japan

(Alliance News) - GSK PLC on Monday said the Japan Ministry of Health, Labour & Welfare has approved Arexvy for adults over 60.

Read more
25 Sep 2023 07:28

GSK's RSV vaccine gets approval in Japan

(Sharecast News) - GSK announced on Monday that its vaccine, Arexvy, has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for preventing respiratory syncytial virus (RSV) disease in adults aged 60 and over.

Read more
19 Sep 2023 09:30

GSK says new HIV PrEP medication authorised by European Commission

(Alliance News) - GSK PLC on Tuesday said the European Commission has authorised ViiV Healthcare's "superior" drug Apretude to reduce the risk of sexually acquired HIV-1 infection.

Read more
18 Sep 2023 09:40

LONDON BROKER RATINGS: Jefferies likes Energean; JPMorgan raises IDS

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
18 Sep 2023 07:57

LONDON BRIEFING: Phoenix Group hails "impressive" first-half

(Alliance News) - Stocks in London are called lower on Monday, as investors focus on the week's upcoming central bank decisions.

Read more
18 Sep 2023 07:18

US FDA approves GSK treatment for myelofibrosis

(Sharecast News) - GSK announced on Monday that the US Food and Drug Administration (FDA) has granted approval for 'Ojjaara', or momelotinib, as a treatment for adults suffering from intermediate or high-risk myelofibrosis with anaemia, including cases of primary myelofibrosis or secondary myelofibrosis.

Read more
15 Sep 2023 21:52

GSK's Ojjaara approved in US for myelofibrosis patients with anaemia

(Alliance News) - GSK PLC on Friday said Ojjaara, also known as momelotinib, has been approved in the US and the "first and only" treatment indicated for myelofibrosis patients with anaemia.

Read more
11 Sep 2023 08:24

Japan accepts GSK's regulatory filing for momelotinib for blood cancer

(Alliance News) - GSK PLC on Monday reported regulatory progress for momelotinib, as Japan's Ministry of Health, Labour & Welfare accepted a review for the blood cancer-focused drug.

Read more
11 Sep 2023 07:54

LONDON BRIEFING: Restaurant Group sells Frankie & Benny's and Chiquito

(Alliance News) - Stocks in London are called higher on Monday, ahead of a busy week of interest rate decisions and economic data.

Read more
6 Sep 2023 09:32

LONDON BROKER RATINGS: Shore says 'buy' B&M; Peel Hunt likes Halfords

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

Read more
4 Sep 2023 06:00

More UK babies to need hospital treatment over delay of GSK's RSV jab

(Alliance News) - The nation's top children's doctor has warned a delay on a new vaccine to combat respiratory syncytial virus, or RSV, will mean more babies and infants will need hospital treatment this winter.

Read more
1 Sep 2023 09:11

GSK antibody accepted for Japan review, Goldman Sachs reduces stake

(Alliance News) - GSK PLC on Friday said a new drug application for its monoclonal antibody mepolizumab has been accepted for review by the Japanese government.

Read more
1 Sep 2023 07:49

LONDON BRIEFING: Stocks seen higher; UK house prices continue to fall

(Alliance News) - Stocks in London are set to open higher on Friday as markets looked ahead to a data-heavy day.

Read more
1 Sep 2023 07:12

Japan considering GSK's Nucala drug for sinusitis treatment

(Sharecast News) - Japanese regulators are reviewing a new drug application for GSK's Nucala treatment to be used for the treatment of form of adult sinusitis, the biopharma giant announced on Friday.

Read more
23 Aug 2023 12:10

LONDON MARKET MIDDAY: Stocks rise but pound slumps on sub-par UK data

(Alliance News) - Stocks in Europe were on the up heading into Wednesday afternoon, with equity markets in a confident mood on the eve of the Jackson Hole central banking event, shaking off tepid economic data which hurt the pound and euro.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.